LONDON (Alliance News) - Synairgen PLC said Wednesday that AstraZeneca PLC has begun a phase IIa study of its AZD9412 compound - which was originally developed by Synairgen and known as SNG001 - in severe asthma.
The trial will build on clinical data from Synairgen's phase IIa study trial in moderate to severe asthma. The development programme was out-licensed to AstraZeneca in June 2014 in a deal worth up to USD232 million plus tiered royalties.
"We are delighted with the progress of the AZD9412 Phase IIa clinical trial and AstraZeneca's commitment to this exciting programme. We look forward to seeing the results in early 2017," said Chief Executive Officer of Synairgen Richard Marsden in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
Synairgen (SNG)